Advertisement

Neurologie pp 589-623 | Cite as

Krankheiten der Basalganglien

  • Daniela Berg
Chapter
  • 17k Downloads
Part of the Springer-Lehrbuch book series (SLB)

Zusammenfassung

Diagnose und Therapie des M. Parkinson und anderer Bewegungsstörungen haben große Fortschritte gemacht: Parallel zur Aufklärung der Funktion der Basalganglien in der Regulation der Motorik sind Genetik, Pathophysiologie und Therapie des M. Parkinson und auch anderer Bewegungsstörungen intensiv erforscht worden. Den Patienten können heute differenzierte Behandlungsprogramme angeboten werden, die die Prognose gegenüber der jüngeren Vergangenheit erheblich verbessern. Dies schließt die elektrische Stimulation (»Schrittmacher«) von extrapyramidalen Kernen (z. B. Ncl. subthalamicus) ein.

Weiterführende Literatur

  1. Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, Brooks D, Burn DJ, Colosimo C, Fanciulli A, Ferreira J, Gasser T, Grandas F, Kanovsky P, Kostic V, Kulisevsky J, Oertel W, Poewe W, Reese JP, Relja M, Ruzicka E, Schrag A, Seppi K, Taba P, Vidailhet M (2013) EFNS/MDS-ES/ENS recommendations for the diagnosis of Parkinson’s disease. Eur J Neurol 20(1):16–34Google Scholar
  2. Berg D, Godau J, Walter U (2008) Transcranial sonography in movement disorders. Lancet Neurol 7(11):1044–55CrossRefGoogle Scholar
  3. Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, Goetz CG, Halliday GM, Hardy J, Lang AE, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G (2014) Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov Disord 29(4):454–62CrossRefGoogle Scholar
  4. Braak H et al. (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24: 197–211CrossRefGoogle Scholar
  5. Dunning CJ, George S, Brundin P (2013) What’s to like about the prion-like hypothesis for the spreading of aggregated α-synuclein in Parkinson disease? Prion 7(1):92–7CrossRefGoogle Scholar
  6. Garcia-Borreguero D1, Ferini-Strambi L, Kohnen R, O’Keeffe S, Trenkwalder C, Högl B, Benes H, Jennum P, Partinen M, Fer D, Montagna P, Bassetti CL, Iranzo A, Sonka K, Williams AM; European Federation of Neurological Societies; European Neurological Society; European Sleep Research Society (2012) European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol 19(11):1385–96CrossRefGoogle Scholar
  7. Goedert M, Spillantini MG, Del Tredici K, Braak H (2013) 100 years of Lewy pathology. Nat Rev Neurol 9(1):13–24CrossRefGoogle Scholar
  8. Mills K, Mari Z (2015) An update and review of the treatment of myoclonus. Curr Neurol Neurosci Rep 15(1):512Google Scholar
  9. Paudel R, Hardy J, Revesz T, Holton JL, Houlden H (2012) Review: genetics and neuropathology of primary pure dystonia. Neuropathol Appl Neurobiol 38(6):520–34CrossRefGoogle Scholar
  10. Perestelo-Pérez L, Rivero-Santana A, Pérez-Ramos J, Serrano-Pérez P, Panetta J, Hilarion P (2014) Deep brain stimulation in Parkinson’s disease: meta-analysis of randomized controlled trials. J Neurol 261(11):2051–60CrossRefGoogle Scholar
  11. Puschmann A, Wszolek ZK (2011) Diagnosis and treatment of common forms of tremor. Semin Neurol 31(1):65–77CrossRefGoogle Scholar
  12. Ross CA, Tabrizi SJ (2011) Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10(1):83–98CrossRefGoogle Scholar
  13. Schaeffer E, Pilotto A, Berg D (2014) Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson’s disease. CNS Drugs 28(12):1155–84CrossRefGoogle Scholar
  14. Schneider SA, Deuschl G (2015) Medical and Surgical Treatment of Tremors. Neurol Clin33(1):57–75CrossRefGoogle Scholar
  15. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 26 Suppl 3:S42–80CrossRefGoogle Scholar
  16. Singleton AB, Farrer MJ, Bonifati V (2013) The genetics of Parkinson’s disease: progress and therapeutic implications. Mov Disord 28(1):14–23CrossRefGoogle Scholar
  17. Sprenger F, Poewe W (2013) Management of motor and non-motor symptoms in Parkinson’s disease. CNS Drugs 27(4):259–72CrossRefGoogle Scholar
  18. Stamelou M, Bhatia KP (2015) Atypical Parkinsonism: Diagnosis and Treatment. Neurol Clin 33(1):39–56CrossRefGoogle Scholar
  19. Wenning GK, Krismer F (2013) Multiple system atrophy. Handb Clin Neurol 117:229–41Google Scholar
  20. Willams DR et al. (2007) Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson’s syndrome. Brain 130(Pt 6):1566–76Google Scholar
  21. Winkelmann et al. (2007) Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Gent 39: 1000–1006Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Daniela Berg
    • 1
  1. 1.Abt. NeurodegenerationHertie-Institut für klinische HirnforschungTübingenDeutschland

Personalised recommendations